– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all.
Cara Therapeutics (CARA) Set to Announce Quarterly Earnings on Monday theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Cara Therapeutics Inc., a Stamford-headquartered commercial-stage biopharmaceutical company focused on creating a new treatment paradigm to improve the lives of patients suffering from pruritus, has entered into a royalty interest purchase and sale agreement with HealthCare Royalty (HCRx), also based in Stamford.
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totalling 2,710,000 shares, a growth of 9.7% from the September 30th total of 2,470,000 shares. Approximately 6.0% of the company’s shares are sold short. Based on an […]